Copenhagen, Denmark, December 15, 2022 /PRNewswire/ — The BioInnovation Institute (BII), an international corporate charitable foundation that creates and accelerates world-class life science research, today announced that it has accepted a new project into its Bio Studio program. Based on recent breakthroughs in artificial intelligence (AI) and protein design, the project is developing a new class of therapeutic proteins to modulate cell signaling using methods developed by David Bakers laboratory at the University of Washington Institute for Protein Design. BII’s Bio Studio program aims to encourage the creation of new life science start-ups based on research by world-class scientists for the benefit of people and society.

BII supports the project with a grant of up to DKK 6.5 million per year for a project period of up to three years and with business development expertise, intellectual property support, access to the investor network and both wet lab and office infrastructure.

Markus Herrgård, Chief Technology Officer at BII, commented on the project: said: “We are very pleased to add this state-of-the-art project to our Bio Studio portfolio. New Protein design is an exciting field that fits perfectly with our strategy to accelerate the commercialization of cutting-edge technology. Our goal is to advance projects that use technology to address unmet medical needs by collaborating with leading research institutions and entrepreneurial academics.”

Lance StewartChief Strategy and Operations Officer at the IPD, added: “We are excited to partner with BII on the first international translational research project to emerge from the Institute for Protein Design $1 billion transforming protein design technologies into effective medicines, and we look forward to continuing to build on this track record with BII’s tremendous support for entrepreneurial scientists.”

The project was conceived by Christopher…